Repaglinide
FDA-approved product (tablet, oral), marketed as Prandin, Repaglinide.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Diabetes mellitus
- Type 2 diabetes mellitus
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other blood glucose lowering drugs, excl. insulins
- FDA pharmacologic class
- Glinide FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA37.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli34.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae27.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis55.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Repaglinide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- FurazolidoneExisting use: Other antiinfectives and antiseptics91.4% AI-predicted activityagainst M. tuberculosisLab records exist49 registered studies
- TriflupromazineExisting use: Psychosis90.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- ValdecoxibExisting use: Dysmenorrhea, Osteoarthritis, Rheumatic disease and 1 more88.6% AI-predicted activityagainst M. tuberculosisLab records exist31 registered studies
- CelecoxibExisting use: Ankylosing spondylitis, Cancer, Colorectal neoplasm and 15 more87.6% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Dorzolamide HydrochlorideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma86.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- MethazolamideExisting use: Glaucoma, Open-angle glaucoma85.6% AI-predicted activityagainst M. tuberculosisLab records exist11 registered studies
- AcetazolamideExisting use: Altitude sickness, Angle-closure glaucoma, Congestive heart failure and 5 more85.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Trifluoperazine HydrochlorideExisting use: Anxiety disorder, Mental or behavioural disorder, Psychosis and 1 more84.6% AI-predicted activityagainst M. tuberculosis1 registered study
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives84.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- NitrofurazoneExisting use: Eye infection, Leishmaniasis, Trypanosomiasis84.0% AI-predicted activityagainst M. tuberculosis8 registered studies
- BrinzolamideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma83.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- ZonisamideExisting use: Epilepsy, Focal-onset seizure, Partial epilepsy and 1 more82.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Efficacy and Safety of Repaglinide Combined With Insulin in Type 2 Diabetes
NCT01720303 · start 2002-09-19
Registered record
- Registry ID
- NCT01720303
- Conditions
- Diabetes; Diabetes Mellitus, Type 2
- Interventions
- repaglinide; isophane human insulin; insulin
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2002-09-19
- Completion
- 2003-04-10
- Enrolment
- 159
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDiabetes; Diabetes Mellitus, Type 2Interventionrepaglinide; isophane human insulin; insulinPhasePhase 4Registry statusCompletedComparison of Repaglinide and Metformin Administered Alone or in Combination in Type 2 Diabetes
NCT01720290 · start 2002-07-25
Registered record
- Registry ID
- NCT01720290
- Conditions
- Diabetes; Diabetes Mellitus, Type 2
- Interventions
- repaglinide; metformin; metformin
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2002-07-25
- Completion
- 2003-02-25
- Enrolment
- 150
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDiabetes; Diabetes Mellitus, Type 2Interventionrepaglinide; metformin; metforminPhasePhase 4Registry statusCompletedComparison of Metformin, Repaglinide or the Combination of Both in Subjects With Type 2 Diabetes
NCT01465152 · start 2002-03-06
Registered record
- Registry ID
- NCT01465152
- Conditions
- Diabetes; Diabetes Mellitus, Type 2
- Interventions
- metformin; repaglinide
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2002-03-06
- Completion
- 2004-10-21
- Enrolment
- 182
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDiabetes; Diabetes Mellitus, Type 2Interventionmetformin; repaglinidePhasePhase 4Registry statusCompletedObservational Study of NovoNorm® in Subjects With Diabetes
NCT01498913 · start 2001-08-30
Registered record
- Registry ID
- NCT01498913
- Conditions
- Diabetes; Diabetes Mellitus, Type 2
- Interventions
- repaglinide
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2001-08-30
- Completion
- 2005-03-25
- Enrolment
- 5,841
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDiabetes; Diabetes Mellitus, Type 2InterventionrepaglinidePhaseNot recordedRegistry statusCompletedEffect of Metformin Versus Repaglinide Treatment in Non-Obese Type 2 Diabetic Patients Uncontrolled by Diet
NCT00118950 · start 2001-03
Registered record
- Registry ID
- NCT00118950
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Metformin; Repaglinide; Placebo-Metformin.; Placebo-Repaglinide.; Diet-only.
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2001-03
- Completion
- 2003-03
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDiabetes Mellitus, Type 2InterventionMetformin; Repaglinide; Placebo-Metformin.; Placebo-Repaglinide. +1 morePhasePhase 4Registry statusCompleted